Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."

QE Necessary, but Not Sufficient for Europe: Gallo
51:05 - Alberto Gallo, head of macro credit research at RBS, discusses expectations of further quantitative easing from the European Central Bank at this week's meeting and what easing can accomplish for Europe's economy. He speaks on "Bloomberg Surveillance." (Source: Bloomberg)
  • Charting a Week that Could Move in a Big Way
  • Is Refugee Help Key to Turkey’s Future with the EU?
  • EU Banks Prepare to Cut Bonuses as JPM Stays Unchanged